Trichostatin A (TSA)

製品コードS1045

Trichostatin A (TSA)化学構造

分子量(MW):302.4

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

サイズ 価格(税別)  
JPY 41002.00
JPY 74202.00
JPY 144420.00

カスタマーフィードバック(6)

  • Gck expression in WT primary hepatocytes transduced with FOXO1 and KR-FOXO1 adenoviruses in the presence or absence of trichostatinA (TSA).

    Cell, 2017, 171(4):824-835.e18. Trichostatin A (TSA) purchased from Selleck.

    Effect of TSA, SAHA and silibinin alone and in combination on left panel: IF staining for p-histone H3 Ser 10 and p-MPM-2 Ser /Thr positive cells and a-tubulin for mitotic spindle and DAPI as nuclear stain in H1299 cells. Right panel: % positive p-histone H3 Ser 10 mitotic cells and expression of p-MPM-2 Ser /Thr protein levels in H1299 cells.

    Epigenetics 2012 7(10):1161-72. Trichostatin A (TSA) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

  • (B) The mRNA level of PRRT2 in the presence of different concentrations of DAC and TSA.

    Biochem Biophys Res Commun, 2017, 485(2):454-460. Trichostatin A (TSA) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM TSA was added.

     

     

    2010 Dr. Zhang of Tianjin Medical University. Trichostatin A (TSA) purchased from Selleck.

製品安全説明書

HDAC阻害剤の選択性比較

生物活性

製品説明 Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
ターゲット
HDAC [1]
(Cell-free assay)
~1.8 nM
体外試験

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 NYn2N5FyTnWwY4Tpc44hSXO|YYm= M{\vcVAvP87:TR?= MnXkNlRp NHP5[GdmfGijbn;s MXLlcohidmOnczDFUoFEKGGlZYT5cIF1cW:wIHHu[EBqdmO{ZXHz[ZMhTU6jQzDhZpVv\GGwY3WgbY4hfGinIITveIFtKGOnbHygcJl{[XSnIHHu[EBifCC2aHWgZ4VtdCC|dYLmZYNm MXyyOVc5PzB5OR?=
TE13 NGnjWGFHfW6ldHnvckBCe3OjeR?= NEPaRYgxNjQQvF2= Ml\xNlRp MnTGeZAuemWpdXzheIV{KFKDU2PGOWEhdGW4ZXy= M{TJTFI2PTd7Nk[1
TE13 NVzZcW9rSXCxcITvd4l{KEG|c3H5 NU\1WFNFOC5|zszN NHXHbHozPGh? NX3vT4QycW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbh?= MX6yOVU4QTZ4NR?=
MEFs Ml7CSpVv[3Srb36gRZN{[Xl? NViwOYRIPc7:TR?= MUKxOog> MYHpcoNz\WG|ZYOgeIhmKEWSRVOgZZR1[WOqbXXueEwhXGm{IHTlcIl3\XK7IHHu[EB1cGViZX\mbYNq\W6leTDv[kBx\WSnc4ThcEBnd3KvYYTpc44> M2jBTlI2PDh{NkO0
SW480  MnrlSpVv[3Srb36gRZN{[Xl? NYDQOXF6OC5zzszN MVm0PIg> NYPrN41MTE2VTx?= MkfadoV3\XK|ZYOgSW1V MVuyOVQ{PDl7Nx?=
PC3  M1XlSmZ2dmO2aX;uJGF{e2G7 M1LCZlAvOc7:TR?= NXLDSYlHPDiq MVnEUXNQ MlS5doV3\XK|ZYOgSW1V MoPkNlU1OzR7OUe=
SW480  NX;TfYxXTnWwY4Tpc44hSXO|YYm= M4TnO|AvOc7:TR?= M2Tqe|Q5cA>? M1fYZmROW09? NH7BO5JifHSnboXheIV{KGmwdnHzbY9vKGGwZDDtbYdz[XSrb36= MnKxNlU1OzR7OUe=
PC3  NHK4TW5HfW6ldHnvckBCe3OjeR?= MWWwMlHPxE1? MonsOFhp NFu4cYZFVVOR NGHQXodifHSnboXheIV{KGmwdnHzbY9vKGGwZDDtbYdz[XSrb36= MV[yOVQ{PDl7Nx?=
SW480  NXTQb|NMTnWwY4Tpc44hSXO|YYm= MXGwMlHPxE1? M1[0ZlQ5cA>? NUDXco9QTE2VTx?= NXPYbmZscW6mdXPld{BqdmO{ZXHz[UBw\iCKRFHDNUBidmRiSFTBR|Ihd25iU3z1[{Bo\W6nczDwdo9ud3Snch?= M1\Me|I2PDN2OUm3
PC3  Mmn6SpVv[3Srb36gRZN{[Xl? NIHPOoExNjIQvF2= MoGwOFhp NX;pNo5ETE2VTx?= Mn3YbY5lfWOnczDpcoNz\WG|ZTDv[kBJTEGFMTDhcoQhUESDQ{Kgc44hW2y3ZzDn[Y5meyCycn;tc5Rmeg>? NYfF[3g5OjV2M{S5PVc>
A431 MlHsRZBweHSxc3nzJGF{e2G7 Mlj0Nk8yOC93MD:xNFBvVQ>? NYHDToRCPDiq M4nm[WROW09? M1nwOYlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aB?= M13ldVI2OzdzME[5
A431 NYS0NWplTnWwY4Tpc44hSXO|YYm= MYC1NI5O NHjiU2gzNzZxMUKvNlRp MYrEUXNQ M3rlNoFkfGm4YYTld{BxOjFiYX7kJIlvcGmkaYTzJGFVTjNiZYjwdoV{e2mxbh?= MVGyOVM4OTB4OR?=
MDA-MB-231 NHT5W25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;EW5VlOC14MEDuUS=> MlrZNlRp MVfEUXNQ NYLm[3ZWUUN3MDDv[kAyODCwTR?= M3y1fVI2OTl{N{Kx
MCF7 NHLwZ3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV70WGdKOC14MEDuUS=> M2HUSVI1cA>? MXfEUXNQ Mkm0TWM2OCCxZjC3OY5O NHfpTWwzPTF7MkeyNS=>
SKOV-3 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVuxMVEx|ryP NUXDT495OjSq MVzEUXNQ MXnJR|UxKG:oIEWuOu69VQ>? MVqyOVE3QTR7MR?=
A549 M3HEcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUexMVEx|ryP M1vUZ|I1cA>? MWnEUXNQ M3jKTmlEPTBib3[gN{4z|ryP M1\qOFI2OTZ7NEmx
SKOV-3 MkHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrKcXVyOC5zLUJOwG0> M{O0SlQ5cA>? NV3IXWdpTE2VTx?= MWHJR|UxKG:oIECuO:69VQ>? MXeyOVE3QTR7MR?=
A549 NHfxWolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVX4SnFIOC5zLUJOwG0> M{n3cVQ5cA>? Mlz4SG1UVw>? M3zY[WlEPTBib3[gNE4zQM7:TR?= MnW3NlUyPjl2OUG=
SKOV-3 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfhRlIxNjBzLUCuPe69VQ>? NVXvTI4zPzKq MV\EUXNQ NH24XZJKSzVyIH;mJFAvOzMQvF2= MnrWNlUyPjl2OUG=
A549 NWG2OFF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPENE4xOS1yLkpOwG0> M{LjSVczcA>? M3XoeWROW09? MVnJR|UxKG:oIECuNFbPxE1? MkH6NlUyPjl2OUG=
HeLa MUjGeY5kfGmxbjDBd5NigQ>? NX;IRlBqOjVybl2= MojoNVZp M3TPUmROW09? NXj4fI9CcW6lcnXhd4V{KEO\UEHBNUBuWk6DIHX4dJJme3Orb39CpC=> MWOyOVEyPjZ6OB?=
CNE2 M4nVNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYixNFAuPjBybl2= NFK3V2szPC92OD:3Nog> MlLQbY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gbY4h[SC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NH;JZlkzPDl4OUmwNS=>
PC3 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXixNFAuOTByMH7N NV:5PWt6OjSq NGXzbpZKSzVyIH;mJFMxOG6P M4jwRlI1QDV2NkW4
LNCaP M1:1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1ntO|ExOC1zMECwcm0> M3zOelI1cA>? MmLsTWM2OCCxZjCzNFBvVQ>? MUGyOFg2PDZ3OB?=
HeLa  MnjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3K4T|LPxE1? NWi5foZwPDiq NYr0WGJQ\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIFjd3W2IEK1KS=> MY[yOFg1PjF|NR?=
HMEC-1  NIraOI5HfW6ldHnvckBCe3OjeR?= MojHN|Axdk1? Mn;5NlRp NFjsOWpqdmO{ZXHz[ZMh\XiycnXzd4lwdiCxZtMgWmVITlJ|wrDtVm5C Mn\iNlQ4OTB4M{G=
HeLa MlvISpVv[3Srb36gRZN{[Xl? NHjwSIoydU1? MlLGNE42cA>? M{XyWoFjd2yrc3jld{B1cGVidH;0ZYwhUESDQzDhZ5Rqfmm2eR?= MWOyOFcxPzR5NB?=
ACP02 MnjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zpflI2OC9|NUCvOVAxdk1? M{i4dVI1cA>? NX7q[Vhk\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JI9nKGGycILvfIlu[XSnbImgO|DDqCViYYSgNlUxyqCwTR?= M4C4eVI1PjZ6NUS3
ACP03 M4\PZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2L4OVI2OC9|NUCvOVAxdk1? NVnCUm9KOjSq M1rBWoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDv[kBieHC{b4jpcYF1\Wy7IEewxsAmKGG2IEK1NOKhdk1? M{Xoc|I1PjZ6NUS3
U87 GBM MmTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVuxNFAwOzByL{WwNEBvVQ>? M3fORVczKGh? M1;SZVExOCViZYToZY5wdA>? NIntSIlz\WS3Y3XzJI1m[W5iY3XscEBvfW2kZYKgZpkhOzFuIEW0MEBidmRiNUlCpEU> NF\HUoczPDR4NEi0NS=>
U87 GBM MoLGSpVv[3Srb36gRZN{[Xl? MXexNFAwPTByIF7t MoHkOFghcA>? NEfNRpgyODBnIHX0bIFvd2x? M4W5T2lv\HWlZYOgV4Vv\XOlZX7j[U1NcWunIFHseIVz[XSrb37zJIlvKE63Y3zlZZIhVW:{cHjvcI9ogQ>? NX\HfY46OjR2NkS4OFE>
RPE NI\BPY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYGwMlIwOC52L{CuPE8yKM7:TR?= MoLUNlQwPDhxN{KgbC=> Mn3sSG1UVw>? M{HyOolvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIJ6KGOnbHygZ5lkdGViYYLy[ZN1 MWiyOFQ2PjZyMh?=
HT29  NXvneVFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vTV|E5OCCwTR?= MnjxO|IhcA>? NXjRRXdMUUN3MDDv[kAyQDBibl2= MUWyOFM3QDJ4NR?=
hMSCs NW\UVVd[TnWwY4Tpc44hSXO|YYm= MmXyOk4zPSCwTR?= M3zoc|I1KGh? M3;XfGROW09? M4fRe5N1[WKrbHn6[ZMhUGm|dH;u[UBC[2W2eXzheIlwdiCjbnSgeIhmKEW6cILld5Nqd25ib3[gVIx2emmyb4TlcpQhT2WwZYO= MmL4NlQ{OTJ|NU[=
Huh7  M1zENmZ2dmO2aX;uJGF{e2G7 M3\wPFAvOS9yLkWvNU4xKM7:TR?= NE\1WmczPGh? MXPzeZBxemW|c3XzJHlVUESFMjDn[Y5mKGW6cILld5Nqd25? MlX1NlQzPjl4N{K=
SKOV3 M1vheGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWqwMlA2NTJizszN MVuxNE8zPC92ODDo NG[5ZmRFVVOR NHnVOmhu\WSrYYTld{Boem:5dHigZZJz\XO2IHnuJIEh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= M2TtPVI1OjJ|OECx
A2780 MnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jTS|AvODVvMjFOwG0> MnrYNVAwOjRxNEigbC=> NY\Ob5NyTE2VTx?= NIC3Ootu\WSrYYTld{Boem:5dHigZZJz\XO2IHnuJIEh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= MYmyOFIzOzhyMR?=
SRA01/04  MnT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrnNY5DOC5{IN88US=> NWjwRWViPDhiaB?= NIfj[mNFVVOR MULzeZBxemW|c3XzJINmdGxicILvcIln\XKjdHnvckB1cHKxdXfoJJN2eHC{ZYPzbY5oKHSqZTDQTVNMN0GtdDygdFM5VUGSSzDhcoQhTVKNMT:yJJNq\26jbHnu[{Bx[XSqd3H5dy=> MWCyOFE2Pzh5OB?=
HLEB3 NVzRNIpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYqwMlIh|ryP NYTFUXBVPDhiaB?= NGi1PHhFVVOR M{TSb5N2eHC{ZYPz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKHSqcn;1[4ghe3WycILld5NqdmdidHjlJHBKO0txQXv0MEBxOziPQWDLJIFv\CCHUluxM|Ihe2mpbnHsbY5oKHCjdHj3ZZl{ MYCyOFE2Pzh5OB?=
SRA01/04  M4HjRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[wNE41NzBwODFOwG0> NGLiPVU1QCCq NHzTeXFFVVOR NV\xeldqcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MWKyOFE2Pzh5OB?=
HLEB3 M2rYZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Xk[VAvPC9yLkig{txO MnzDOFghcA>? NGjqbVRFVVOR NGDNSIZqdmS3Y3XzJINmdGxiYYDvdJRwe2m| M3PsSVI1OTV5OEe4
HCT116 M33DT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWewMlIh|ryP M2PxW|EzKGh? MV;lcohidmOnczDj[YxtKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IILh[IlifGmxbh?= NWTPbmFkOjRzMkKyN|E>
CA46 NX\6T5J1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYSzM|YwOTJxMkSvOFghdk1? NG\0OnU1QCCq M1HvW4lvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iYYSgNlQh[W6mIES4JI5OyqB? NFH3VXMzPDB4NEm1NS=>
PMNs NELK[IVHfW6ldHnvckBCe3OjeR?= Mn\lN|Ahdk1? MVm0PEBp MojSbY5pcWKrdIOg[YZn\XKxY4n0c5NqeyxiSFTBR{Bi[3Srdnn0fUBidmRiUnHjJIFkfGm4aYT5 MYKyN|k5QDZzNx?=
H1299 M1fIVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrnNeKh|ryPwrC= MnHRNlQwPDhxN{KgbC=> NYHqXHY2\XSqYX7vcC=> M3m3Uolv[3KnYYPld{Bk\WyuIHTlZZRpKGGodHXyJFI1cA>? M36xRVI{QTF4NkC5
A549 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPKdWJ3OC5{NT:wMlUwOSEQvF2= M3P2clI1NzR6L{eyJIg> MnzH[ZRp[W6xbB?= MkizbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHnuJINwdmOnboTyZZRqd25iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? M1jXbVI{QDZ5OUmx
H1299 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml72NE4zPS9yLkWvNUDPxE1? M{jPZlI1NzR6L{eyJIg> M1Lr[IV1cGGwb3y= NFnRbolqdmirYnn0d{B1cGViY3XscEBoem:5dHigbY4h[2:wY3XueJJifGmxbjDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ M2PGeVI{QDZ5OUmx
A549 MYXBdI9xfG:|aYOgRZN{[Xl? NE\yPXMxNjVxMTFOwG0> NF32N5k1QCCq MVvleIhidm:u MX\pcoR2[2W|IHPlcIwh[XCxcITvd4l{ MUmyN|g3Pzl7MR?=
H1299 MVzBdI9xfG:|aYOgRZN{[Xl? MXqwMlUwOSEQvF2= MVS0PEBp MXXleIhidm:u MmG2bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M3rMOVI{QDZ5OUmx
SUM149PT M1;1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzNO3EzNzdwNT:xNEDPxE1? Mmf5OFghcA>? MmjvSG1UVw>? MYfpcoR2[2W|IHPlcIwh\GWjdHigZZQhOiEQvF2gbY5{\W6|aYTpeoVtgQ>? M4PHbVI{Pzl{NkO4
SUM190PT NEDkd4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVq1NE8yODBxMkWwJI5O MYi0PEBp M4TVeWROW09? M1;sd4lv\HWlZYOgZ4VtdCCmZXH0bEBifCB3MDDuUUB{\W6|aYTpeoVtgQ>? Mn7yNlM4QTJ4M{i=
HCT1 MkC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXsNE4zNzFwMD:1MlAh|ryP NXn1OVRJOTJxMkSvN|YwPDhiaB?= NXTkdVRUcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> M{\6dFI{PzdyMECw
Lovo M1fERWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rkfFAvOi9zLkCvOU4xKM7:TR?= MnO3NVIwOjRxM{[vOFghcA>? MkfrbY5lfWOnczDj[YxtKGSnYYToJIlvKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NWT2[GVOOjN5N{CwNFA>
AGS M17kS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzNXow3OC5yMUWtNUDPxE1? NHqyVlM4OiCq M4rSXIlv\HWlZYOgZ4VtdCCmZXH0bEBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5 NX\6c2JYOjN5NEWwNlQ>
Huh7 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDjWlN2OSEQvF2= M{TsRVI1KGh? NICxZoZFVVOR NXnDSYN1emWmdXPld{Bi[m:3dDCyNEUhfmmjYnnsbZR6yqB? NF7nNXMzOzZ2M{mzNy=>
ECC1 NYLMRlNbTnWwY4Tpc44hSXO|YYm= NVH6[HdrPTByIH7N M4HWXFUh\A>? MoPtSG1UVw>? M{L1[4lv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF MkezNlM2OzB5Nkm=
HEC1A M1v3TWZ2dmO2aX;uJGF{e2G7 NWrnZXdJPTByIH7N M3TaTlUh\A>? MXzEUXNQ Mn\lbY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? M3HDOVI{PTNyN{[5
EN1 MUDGeY5kfGmxbjDBd5NigQ>? NIK1cFY2ODBibl2= MlTCOUBl NVWxU3I3TE2VTx?= MYjpcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? MXeyN|U{ODd4OR?=
MFE296 NXr6W2d3TnWwY4Tpc44hSXO|YYm= M4TrPVUxOCCwTR?= Mnj0OUBl MX3EUXNQ MU\pcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? MonENlM2OzB5Nkm=
HASMCs NE\m[4ZHfW6ldHnvckBCe3OjeR?= MWmwMVUxOCCwTR?= MXu2JIQ> M125S4Rwf25vcnXneYxifGW|IITo[UBmgHC{ZYPzbY9vKG:oIFjBSGMh[W6mIHPlcIwhfmmjYnnsbZR6 Mn\1NlM2OTh2Nke=
U373 MnfKSpVv[3Srb36gRZN{[Xl? NWXUPHdQOC5{NT:wMlUwOSEQvF2= M{faSlI1KGh? M1fuPYlv[3KnYYPld{BRWi2EIHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOWF7[WSF NF3XN3UzOzR5NEG3NS=>
ARN8  MoLUSpVv[3Srb36gRZN{[Xl? M4HYOFAvODVvMjFOwG0> NHLpTlIzPCCq NF3mOo1z\WS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gdFU{NWSncHXu[IVvfCCpZX7ld{BjgSCQdYTsbY4uOw>? Ml2yNlM1PzB3NEC=
MCF7 NFHHcolHfW6ldHnvckBCe3OjeR?= MWGwMlA2NTJizszN NGnmVo0zPCCq MYry[YR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZicEWzMYRmeGWwZHXueEBo\W6nczDifUBPfXSuaX6tNy=> M4nJeVI{PDdyNUSw
H1299  MXzGeY5kfGmxbjDBd5NigQ>? NHe1[|ExNjN|4pETNeKhyrWP MoT2NlQwPDhiaB?= M2fQcWROW09? NInk[YZqdmO{ZXHz[ZMhTS2lYXTo[ZJqdiCycn;0[YlvKGyndnXsd{Bld3OnIHTldIVv\GWwdHz5 NUfyXYhDOjN2NkG5O|U>
H1299 M{XMUGZ2dmO2aX;uJGF{e2G7 NIrlUIcxNjVizszN MVq0PEBp MlPzSG1UVw>? MYjpcohq[mm2czD0bIUhdWmpcnH0c5J6KHCxdHXueIlidCClb33ibY5mKHerdHigd4ltcWKrbnnu MYCyN|Q3OTl5NR?=
H1299 M{Dpb2Z2dmO2aX;uJGF{e2G7 MXewMlUh|ryP MnfGOFghcA>? M{D5[GROW09? M3rwZolvcGmkaYTzJJRp\SCrbo\hd4l3\W6nc4RCpEBkd22kaX7lJJdqfGhic3nsbYJqdmmw NWfORWZvOjN2NkG5O|U>
MG-63  MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3O5T|AvOyEQvF2= MnH2NVIuQTZiaB?= M4TwS2ROW09? M1\MV4lvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDjc{11emWjdH3lcpQhf2m2aDDt[ZRnd3KvaX6= MXSyN|Q2OThzNx?=
LM8 MnrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13ic|AvOyEQvF2= M1jJdFEzNTl4IHi= M4PDNWROW09? Mne1bY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHPvMZRz\WG2bXXueEB4cXSqIH3leIZwem2rbh?= MlL0NlM1PTF6MUe=
K562 MWPGeY5kfGmxbjDBd5NigQ>? MXWwMlUh|ryP MUmyOEBp NXnaOIFZ\XSqYX7vcC=> NWPZcZBx\GWlcnXhd4V{KHSqZTDlcpp6dWViYXP0bZZqfHlib3[gTGRCS3NiY3:teJJm[XSvZX70JJdqfGhiY4XyZ5VucW5? M3XM[VI{PDNyOUW3
HEL MoLmSpVv[3Srb36gRZN{[Xl? NVz4[FdROC53IN88US=> NXS0O5FYOjRiaB?= M{LOWoV1cGGwb3y= Ml\k[IVkemWjc3XzJJRp\SCnbor5cYUh[WO2aY\peJkhd2ZiSFTBR5Mh[29vdILlZZRu\W62IIfpeIgh[3W{Y4XtbY4> NYD2fXhTOjN2M{C5OVc>
HL60 Mlj2RZBweHSxc3nzJGF{e2G7 NXnmXpRlOSEQvF2= MVOyOEBp NVn1VWhycW6mdXPld:Kh[2WubDDk[YF1cA>? M3j0TlI{PDByNUG5
KG1 NVriWFhZSXCxcITvd4l{KEG|c3H5 NYPaVFJ2OSEQvF2= MXiyOEBp M1fKPYlv\HWlZYRCpINmdGxiZHXheIg> NHe2bWMzOzRyMEWxPS=>
Kazumi MlTQRZBweHSxc3nzJGF{e2G7 M{XhS|Eh|ryP Mm\jNlQhcA>? NFjtSYZqdmS3Y3XzxsBk\WyuIHTlZZRp MXyyN|QxODVzOR?=
K562 NHy3VXNCeG:ydH;zbZMhSXO|YYm= MVixJO69VQ>? MlLHNlQhcA>? MofYbY5lfWOnc9MgZ4VtdCCmZXH0bC=> M330dVI{PDByNUG5
THP1 MX\BdI9xfG:|aYOgRZN{[Xl? MWGxJO69VQ>? MnzXNlQhcA>? MXnpcoR2[2W|wrDj[YxtKGSnYYTo M1PFNFI{PDByNUG5
SH-SY5Y M4ToN2Z2dmO2aX;uJGF{e2G7 MnzkNlUxKG6P MUSxOkBp MWrjbIFv\2W|IHX4dJJme3Orb36gdIF1fGW{bjDv[kBo\W6nczDpcpZwdH[nZDDpckBkcG:uZYP0[ZJwdCC|eX70bIV{cXNuIIXweIFs\SCjbnSg[YZndHW6 M1v2UlI{OzJ4NEKy
HEK293 MVzGeY5kfGmxbjDBd5NigQ>? MXWxJOK2VcLi NHrFR3YyQCCqwrC= M4nqRYlvcGmkaYTzJJRp\SCtYXzpdolvNTdvbXXkbYF1\WRicnXjdpVqfG2nboSgc4Yhe3mwcHjpcIlvNTFiYXfndoVo[XSnczDpcpRwKGGpZ4Lld49u\XN? MmfLNlMzQDR6NEi=
HTK M{XFNmZ2dmO2aX;uJGF{e2G7 NYGwVJBrPDByIH7N MUC3NkBp NIr1PVRqdmirYnn0d{BVT0ZvzsNihLNKdmS3Y3XkJG16d2[rYoLvZoxie3RiRHnm[oVz\W62aXH0bY9v MYqyN|I5PDByMh?=
HTK MkXoSpVv[3Srb36gRZN{[Xl? M1XZXVExOC16MEDuUS=> NX31SJBRPzJiaB?= M2HkZoJtd2OtczDUS2Yu|rMkgKPJcoR2[2WmIGLPV{BidmRiSELPNuKhSWOldX31cIF1cW:w M3jvc|I{Ojh2MECy
Caco-2  MoDLSpVv[3Srb36gRZN{[Xl? NX3IPYF2OSEEtV5CpC=> NFnHRYUzPCCq NXnqcHJr\GWlcnXhd4V{KFOHUmSgdJJwfGWrbjDlfJBz\XO|aX;u NXTWemxIOjNzOUWwO|A>
HeLa NXvNOYxQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXT6dodQOTByIH7N NFfZS28zPCCq NH7ZN|NFVVOR NWXBN|lXUUN3MDDv[kAyODCwTR?= NUPzN|dKOjNzNkW3OFg>
HeLa MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4S4XlQxKG6P NYHRU|NyPDhiaB?= MnH6SG1UVw>? M{LlWWlEPTBib3[gOFBvVQ>? NVHBeGpsOjNzNkW3OFg>
HeLa MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NID0bIQzOCCwTR?= NInxdo04OiCq Ml60SG1UVw>? NYL4bXY3UUN3MDDv[kAzOG6P M4nSRlI{OTZ3N{S4
HeLa NX\oToJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjQZ4tDOTBxM{CvOVAhdk1? MmrMO|IhcA>? NWj1cXZ4TE2VTx?= NXnpfYlScW6lcnXhd4V{KHSqZTDueY1j\XJib3[gUW1RKCkQlN8ocUkhdG:|czDj[YxteyCmb4PlJIRmeGWwZHXueIx6 M{XUPVI{OTZ3N{S4
MDA-MB-231 NHrq[YJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXlNlUuPDByIH7N MYi0PEBp NX\5PHlpUUN3MDDv[kAzPjNwMn7NxsA> MYWyN|A2PTF7OB?=
MCF-7  NEDzV41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7l[Zl{OjVvNECwJI5O MoPJOFghcA>? NV;5cnl{UUN3MDDv[kAzOjBwNH7N M1zoUVI{ODV3MUm4
ECC-1  NH3sVmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfmS5gyODBibl2= MVeyOEBp MXjleIhidm:u NHfxbGpqdmO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4Yh[XCxcITveIlkKG63Y3zlbUB1dyB|NTW= M2rmcVI{ODJ6OECz
HEC-1A NVfGTFBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTVNVAxKG6P NWHsS4pSOjRiaB?= M{C3foV1cGGwb3y= M1nleYlv[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBieG:ydH;0bYMhdnWlbHXpJJRwKDN7JR?= NV:yRldQOjNyMki4NFM>
NHAC-kn MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnruNVAwOTByL{WwNEBvVQ>? NVrhdHlrOTJiaB?= MlzpSG1UVw>? M3GyT2lEPTBib3[gOVAxdk1? Mm\KNlMxOTd6N{G=
A549 NWjHNFB5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXRUGduOjVyIH7N MorIOk04OiCq NX2xOGlHTE2VTx?= MknzZ4F2e2W|IHGg[5Jm[XSncjDpcohq[mm2b4L5JIVn\mWldDDjc41jcW6nIIfpeIghXFiWIH;yJIVzdG:2aX7pZi=> MXWyNlk6PDd6MB?=
MG-63 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7QfJFOOzByIH7N M3L1fFEzKGh? M2jBfWROW09? M2XLOolvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDD0c{A5PiV? NHjmdVYzOjd7OUOzPC=>
MG-63 NEDMWFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13MelMxOCCwTR?= Mkn4NlQhcA>? NVPoelFoTE2VTx?= MWLpcohq[mm2czD0bIUh[2WubDDndo94fGhidH:gOlcm NVWyd4tCOjJ5OUmzN|g>
MG-63 MoHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnThN|AxKG6P MoCyOFghcA>? MXrEUXNQ MofSbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFU3LQ>? NV7FTJlyOjJ5OUmzN|g>
HL60  NVu3PHZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVSxNWpkOTVyLUO1NEBvVQ>? MXiyOEBp Mlz1bY5kemWjc3XzJINmdGxiYYDvdJRwe2m|wrD3bIVvKGOxbnPlcpRz[XSrb37zJIhq\2incjD0bIFvKDJ3MDDuUS=> NWPt[|Q3OjJ5NUO3N|k>
U937 Mli0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYGxOVAuOzVyIH7N M3PnSVI1KGh? NEjDNYNqdmO{ZXHz[ZMh[2WubDDhdI9xfG:|aYRCpJdp\W5iY3;uZ4VvfHKjdHnvcpMhcGmpaHXyJJRp[W5iMkWwJI5O MnnRNlI4PTN5M{m=
SCC-6 MoH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXmyNFAuOzJyMDDuUS=> MkHoNVIwOjRxNEigbC=> MVPEUXNQ NUXlc4FZcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hd2ZiU1PDMVYh[2WubIOgbY4h[SCmb4PlMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy M4LXTVIzPTV{M{Kx
U87  NF[5RndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrybVIyODBvM{CwJI5o M4XqZlI1KGh? NEjFcJNqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPzJnIDDheEAzODCwZx?= NHPDTpYzOjJ5MEi0PS=>
K562 MVXGeY5kfGmxbjDBd5NigQ>? MlfsNUDPxE1? MXixNkBp MXXEUXNQ NFntWlRmdmijbnPld{B1cGViZYjwdoV{e2mxbjDv[kBTXU6[MzDpcoR2[2WmIHL5JFUu[XqjLVPkVi=> MVyyNlE4QTF7OB?=
Reh MVzGeY5kfGmxbjDBd5NigQ>? NXvS[3c2OC5|L{Gg{txO MXyxNkBp MYXEUXNQ MXrlcohidmOnczD0bIUh\XiycnXzd4lwdiCxZjDSWW5ZOyCrbnT1Z4VlKGK7IEWtZZpiNUOmUh?= MluzNlIyPzlzOUi=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

In vitro HDAC activity:

Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
細胞試験:

[1]

+ 展開
  • 細胞株: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
  • 濃度: Dissolved in absolute ethanol, final concentrations ~10 μM
  • 反応時間: 96 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
  • 製剤: Dissolved in DMSO
  • 投薬量: ~5 mg/kg/day
  • 投与方法: Injection s.c.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 23 mg/mL (76.05 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
3mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 302.4
化学式

C17H22N2O3

CAS No. 58880-19-6
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03735173 Not yet recruiting Arthropathy Shoulder|Shoulder Pain|Shoulder Osteoarthritis|Shoulder Arthritis|Shoulder Arthropathy Associated With Other Conditions|Necrosis of Bone|Arthritis|Inflammatory Arthritis Mayo Clinic December 1 2018 Not Applicable
NCT02959905 Unknown status Metastatic Melanoma BGI China|Sun Yat-sen University December 2016 Phase 1
NCT03133819 Enrolling by invitation Diabetes; Neuropathy Polyneuropathy (Manifestation) Chang Gung Memorial Hospital November 2016 Not Applicable
NCT02486965 Recruiting Fibromyalgia University Hospital Brest October 2015 Not Applicable
NCT01954433 Active not recruiting Glenohumeral Arthritis and/or Rotator Cuff Tear Arthropathy (TSA)|Rotator Cuff Tear (RCR)|Trapeziometacarpal Osteoarthritis (TMC OA) Matthias Flury|Winterthur Institute of Health Economics (WIG) Switzerland|Schulthess Klinik November 2013 --
NCT01575106 Completed Pain Massachusetts General Hospital June 2012 Not Applicable

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • 回答:

    Our S1045 Trichostatin A (TSA) is R enantiomer.

HDACシグナル伝達経路

HDAC Inhibitors with Unique Features

相関HDAC製品

Tags: Trichostatin A (TSA)を買う | Trichostatin A (TSA) ic50 | Trichostatin A (TSA)供給者 | Trichostatin A (TSA)を購入する | Trichostatin A (TSA)費用 | Trichostatin A (TSA)生産者 | オーダーTrichostatin A (TSA) | Trichostatin A (TSA)化学構造 | Trichostatin A (TSA)分子量 | Trichostatin A (TSA)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID